Reactive27

Support Analyst. IT Systems. Day Trader. Be the best at what you love

[Ade 📊🤍 @Ade_Cryptoh]

🎶 Why not turn up the volume on $AUDIO?
Sitting on strong support + retesting zone with bullish momentum 📈

Bias: Long ✅

#Audio #Altcoins

[Reactive27 @Reactive27]

$Toshi - Here we go 🚀🚀🚀🚀

[Reactive27 @Reactive27]

Just the beginning $Toshi

[Life Science Report @lifesciencerpt]

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis $TAK https://t.co/jNe797fdNR

[Big4Bio @big4bio]

Highlights from today's #LosAngeles life science newsletter: Takeda $TAK Signs Deal with AcuraStem; SOHM $SHMN Acquires Gene Editing Company ABBIE; Lixte's Announces New President and CEO.

Stay up to date on all #LA biotech news here: https://t.co/ZjFGhF3p8K #biotech

[pharmaphorum @pharmaphorum]

. @TakedaPharma sets its sights on neurodegenerative disorder #ALS via a $580m licensing deal with US #biotech @AcuraStem, headed by #PIKfyve inhibitor AS-202 $TAK

https://t.co/7ohwfFNbaH

[Reactive27 @Reactive27]

$TAK
https://t.co/qsQKek0pT1

[FirstWord Pharma @fwpharma]

Takeda partners with AcuraStem on ALS drug development for up to $580 million $TAK https://t.co/7QC5xkZfIf

[Reactive27 @Reactive27]

$tak - Massive Volume

[Reactive27 @Reactive27]

@elonmusk $TAK

[stock setter @MarcJacksonLA]

$RHHBY $TAK
Roche scores—again—in hemophilia drug patent case against Takeda https://t.co/ImcsLiSK40

[stock setter @MarcJacksonLA]

$TAK
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
https://t.co/dIGC6h2hV3 via @PharmaTechFocus

[Reactive27 @Reactive27]

$BRGC - News will send this flying

[Life Science Report @lifesciencerpt]

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia $TAK https://t.co/frMV4AaMAP

[Briefing.com @Briefingcom]

$TAK: Takeda Pharma announces approval of CUVITRU subcutaneous immunoglobulin in Japan for patients with... https://t.co/iGTnAwZ1jl

[Reactive27 @Reactive27]

$TAK - Expecting great news

[Briefing.com @Briefingcom]

$TAK: Takeda Pharma announces FDA acceptance of BLA for subcutaneous administration of ENTYVIO (vedolizumab) for... https://t.co/bUihxohgkx

[Reactive27 @Reactive27]

@GlobalTechGTLL Nothing ground breaking about this company. When this company stops giving notes out and reduces the share structure down to about 2 billion the things will be exciting. Right now its a pure scam.

[Reactive27 @Reactive27]

@GlobalTechGTLL This is the biggest scam in stock trading history. 14 billion shares, dilution and nothing good coming for share holders. Run from this company dump your shares